MET is altered in 2.83% of malignant solid tumor patients with MET Mutation present in 2.02% of all malignant solid tumor patients [4].

MET Mutation is an inclusion criterion in 18 clinical trials for malignant solid tumor, of which 8 are open and 10 are closed. Of the trials that contain MET Mutation and malignant solid tumor as inclusion criteria, 10 are phase 1 (2 open), 3 are phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [5].

MET is altered in 5.01% of non-small cell lung carcinoma patients with MET Mutation present in 2.7% of all non-small cell lung carcinoma patients [4].

MET Mutation is an inclusion criterion in 17 clinical trials for non-small cell lung carcinoma, of which 8 are open and 9 are closed. Of the trials that contain MET Mutation and non-small cell lung carcinoma as inclusion criteria, 7 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (3 open), and 1 is phase 3 (0 open) [5].

MET is altered in 6.7% of melanoma patients with MET Mutation present in 6.02% of all melanoma patients [4].

MET Mutation is an inclusion criterion in 4 clinical trials for melanoma, of which 3 are open and 1 is closed. Of the trials that contain MET Mutation and melanoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [5].

MET is altered in 2.69% of cancer patients with MET Mutation present in 1.92% of all cancer patients [4].

MET Mutation is an inclusion criterion in 4 clinical trials for cancer, of which 2 are open and 2 are closed. Of the trials that contain MET Mutation and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 3 are phase 1 (2 open) [5].

MET is altered in 2.14% of colorectal carcinoma patients with MET Mutation present in 1.83% of all colorectal carcinoma patients [4].

MET Mutation is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 1 is open and 3 are closed. Of the trials that contain MET Mutation and colorectal carcinoma as inclusion criteria, 3 are phase 1 (0 open) and 1 is phase 2 (1 open) [5].

MET is altered in 1.14% of breast carcinoma patients with MET Mutation present in 0.95% of all breast carcinoma patients [4].

MET Mutation is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 2 are open and 2 are closed. Of the trials that contain MET Mutation and breast carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

MET is altered in 2.59% of hepatocellular carcinoma patients with MET Mutation present in 0.94% of all hepatocellular carcinoma patients [4].

MET Mutation is an inclusion criterion in 4 clinical trials for hepatocellular carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MET Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [5].

MET is altered in 4.12% of glioblastoma patients with MET Mutation present in 2.85% of all glioblastoma patients [4].

MET Mutation is an inclusion criterion in 3 clinical trials for glioblastoma, of which 1 is open and 2 are closed. Of the trials that contain MET Mutation and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

MET is altered in 2.77% of bladder carcinoma patients with MET Mutation present in 2.59% of all bladder carcinoma patients [4].

MET Mutation is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET Mutation and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

MET is altered in 2.08% of head and neck carcinoma patients with MET Mutation present in 1.94% of all head and neck carcinoma patients [4].

MET Mutation is an inclusion criterion in 3 clinical trials for head and neck carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET Mutation and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

MET is altered in 1.29% of prostate carcinoma patients with MET Mutation present in 1.06% of all prostate carcinoma patients [4].

MET Mutation is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MET Mutation and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

MET is altered in 4.83% of endometrial carcinoma patients with MET Mutation present in 4.5% of all endometrial carcinoma patients [4].

MET Mutation is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

MET is altered in 3.94% of renal cell carcinoma patients with MET Mutation present in 2.7% of all renal cell carcinoma patients [4].

MET Mutation is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

MET is altered in 2.75% of head and neck squamous cell carcinoma patients with MET Mutation present in 2.67% of all head and neck squamous cell carcinoma patients [4].

MET Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

MET is altered in 3.25% of squamous cell lung carcinoma patients with MET Mutation present in 2.2% of all squamous cell lung carcinoma patients [4].

MET Mutation is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (1 open) [5].

MET is altered in 1.59% of ovarian carcinoma patients with MET Mutation present in 1.33% of all ovarian carcinoma patients [4].

MET Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

MET is altered in 1.36% of lymphoma patients with MET Mutation present in 1.16% of all lymphoma patients [4].

MET Mutation is an inclusion criterion in 2 clinical trials for lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MET Mutation and lymphoma as inclusion criteria, 2 are phase 1 (0 open) [5].

MET is altered in 1.48% of soft tissue sarcoma patients with MET Mutation present in 1.0% of all soft tissue sarcoma patients [4].

MET Mutation is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain MET Mutation and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].

MET is altered in 0.89% of pancreatic carcinoma patients with MET Mutation present in 0.76% of all pancreatic carcinoma patients [4].

MET Mutation is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

MET is altered in 16.9% of papillary renal cell carcinoma patients with MET Mutation present in 12.68% of all papillary renal cell carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and papillary renal cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

MET is altered in 3.8% of malignant uterine neoplasm patients with MET Mutation present in 3.51% of all malignant uterine neoplasm patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 4.95% of lung carcinoma patients with MET Mutation present in 2.7% of all lung carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 2.83% of urothelial carcinoma patients with MET Mutation present in 2.62% of all urothelial carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 2.26% of cervical squamous cell carcinoma patients with MET Mutation present in 2.26% of all cervical squamous cell carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 3.12% of glioma patients with MET Mutation present in 2.25% of all glioma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 1.89% of cervical carcinoma patients with MET Mutation present in 1.89% of all cervical carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 2.48% of anaplastic astrocytoma patients with MET Mutation present in 1.81% of all anaplastic astrocytoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains MET Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MET is altered in 3.56% of gastric adenocarcinoma patients with MET Mutation present in 1.56% of all gastric adenocarcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 3.53% of gastric carcinoma patients with MET Mutation present in 1.54% of all gastric carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MET Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MET is altered in 1.49% of gliosarcoma patients with MET Mutation present in 1.49% of all gliosarcoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 2.1% of esophageal squamous cell carcinoma patients with MET Mutation present in 1.4% of all esophageal squamous cell carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 1.61% of high grade ovarian serous adenocarcinoma patients with MET Mutation present in 1.23% of all high grade ovarian serous adenocarcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 4.29% of adenocarcinoma of the gastroesophageal junction patients with MET Mutation present in 1.14% of all adenocarcinoma of the gastroesophageal junction patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 1.12% of medulloblastoma patients with MET Mutation present in 1.12% of all medulloblastoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 1.03% of Ewing sarcoma patients with MET Mutation present in 1.03% of all Ewing sarcoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 0.99% of mesothelioma patients with MET Mutation present in 0.99% of all mesothelioma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 1.39% of sarcoma patients with MET Mutation present in 0.99% of all sarcoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MET Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MET is altered in 0.93% of multiple myeloma patients with MET Mutation present in 0.93% of all multiple myeloma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 0.9% of pancreatic adenocarcinoma patients with MET Mutation present in 0.77% of all pancreatic adenocarcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 1.82% of gallbladder carcinoma patients with MET Mutation present in 0.73% of all gallbladder carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 0.95% of B-cell non-hodgkin lymphoma patients with MET Mutation present in 0.69% of all B-cell non-hodgkin lymphoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 0.69% of osteosarcoma patients with MET Mutation present in 0.69% of all osteosarcoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 0.63% of thyroid gland medullary carcinoma patients with MET Mutation present in 0.63% of all thyroid gland medullary carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 0.6% of adrenal cortex carcinoma patients with MET Mutation present in 0.6% of all adrenal cortex carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for adrenal cortex carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and adrenal cortex carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 1.7% of bile duct carcinoma patients with MET Mutation present in 0.57% of all bile duct carcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 1.7% of cholangiocarcinoma patients with MET Mutation present in 0.57% of all cholangiocarcinoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 2.46% of rhabdomyosarcoma patients with MET Mutation present in 0.49% of all rhabdomyosarcoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Mutation is an inclusion criterion in 1 clinical trial for alveolar soft part sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and alveolar soft part sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Mutation is an inclusion criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Mutation is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Mutation is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 2.31% of mucosal melanoma patients [4].

MET Mutation is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Mutation is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MET Mutation and Wilms tumor as inclusion criteria, 1 is phase 2 (1 open) [5].